Oxford Nanopore’s Gene Sequencer Facing Technical Delays

Oxford Nanopore Technologies Ltd., the company in a race with Illumina Inc. (ILMN) and Life Technologies Corp. (LIFE) to develop smaller, cheaper and quicker gene-sequencing devices, is facing technical setbacks.

Oxford Nanopore, based in Oxford, England, has had to redesign components of a custom sensor because it wasn’t performing satisfactorily, which has lengthened development and testing periods, according to a post yesterday on the blog Pathogens: Genes and Genomes. The blog is found on the University of Birmingham’s website and written by Nick Loman, a doctor who works as a bioinformatics specialist at the English university.

“That put us back about five months, but it was the right thing to do,” Loman quoted Oxford Nanopore Chief Technology Officer Clive Brown as saying at the Advances in Genome Biology and Technology conference last month.

The closely held company said more than a year ago that it expected to begin selling its products by the end of 2012. Yesterday, it didn’t deny Loman’s account of his conversation with Brown when contacted by Bloomberg News.

“We should have made it clear that was off the record,” Chief Executive Officer Gordon Sanghera said of Loman’s report. “We aren’t giving any further comment on it.”

The company has also had to address chemistry in its devices degrading and has been striving to reduce the error rate to 1 percent from 4 percent, according to Loman’s account of his conversation with Brown, which took place during the Feb. 20-23 AGBT meeting in Marco Island, Florida.

Technical Risks

IP Group Plc (IPO) owns about 20 percent of Oxford Nanopore. Competitor Illumina owns about 15 percent, and the company’s other shareholders include hedge-fund manager Lansdowne Partners LP and Invesco Perpetual, the U.K. group of mutual funds.

Numis Securities’ London-based analyst Charles Weston reduced his estimate of Oxford Nanopore’s value by 25 percent to $1.5 billion from $2 billion in a Feb. 20 note to clients, citing technical-development risks.

Loman wrote that Brown told him the device wouldn’t be “a year, two years late” and that the company would release data from its early-access program for its products this year.

Oxford Nanopore was spun out of Oxford University in 2005 and its technology was initially based on research by Hagan Bayley, a professor of chemical biology at the university. Its instruments use a novel technique known as strand sequencing, in which an entire string of DNA is guided by an enzyme and passes intact through a tiny hole in a cell membrane one-billionth of a meter wide.

To contact the reporter on this story: Andrea Gerlin in London at agerlin@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.